The Latest Breaking News from AbbVie

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 12 strange trades.

As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.

Growing concerns over sky-high inflation, the Fed’s aggressive interest rate hikes, the decline in GDP for two consecutive quarters, and increasing odds of a recession are expected to keep the stock market under tremendous pressure in the near term. Amid this backdrop, investing in fundamentally sound stocks AbbVie (ABBV), Acuity…

Here's a roundup of top developments in the biotech space over the last 24 hours:

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 18 strange trades.

AbbVie leaned heavily on immunology drugs in the second quarter, helping offset declines for key drugs. But AbbVie stock fell early Friday.

While most medical attention has been on COVID, work has been underway to eliminate another viral disease, hepatitis C.